WO1996020702B1 - The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome - Google Patents
The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndromeInfo
- Publication number
- WO1996020702B1 WO1996020702B1 PCT/US1995/016892 US9516892W WO9620702B1 WO 1996020702 B1 WO1996020702 B1 WO 1996020702B1 US 9516892 W US9516892 W US 9516892W WO 9620702 B1 WO9620702 B1 WO 9620702B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- respiratory distress
- distress syndrome
- adult respiratory
- treating adult
- ards
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
This invention relates to methods for treating Adult Respiratory Distress Syndrome (ARDS) which involves the administration of 2,3-alkylcarbonyloxybenzoic acid and salts thereof wherein the alkyl group has 2-18 carbon atoms.
Claims
1. A method for treating Adult Respiratory Distress Syndrome (ARDS) comprising administering to a subject in need of ARDS therapy an effective therapeutic amount of 2,3-alkylcarbonyloxybenzoic acid and salts thereof wherein the alkylcarbonyl group has 12-18 carbon atoms.
2. The method of Claim 1, wherein ibuprofen is administered in combination with 2,3-alkylcarbonyloxybenzoic acid.
3. A pharmaceutical composition for treating Adult Respiratory Distress Syndrome (ARDS) comprising 2,3-alkylcarbonyloxybenzoic acid or salts thereof wherein the alkylcarbonyl group has 2-18 carbon atoms.
4. The pharmaceutical composition of Claim 3, further comprising ibuprofen.
5. A pharmaceutical composition for treating Adult Respiratory Distress Syndrome (ARDS) comprising an effective therapeutic amount of 2,3- alkylcarbonyloxybenzoic acid or salts thereof and ibuprofen.
6. The pharmaceutical composition of Claim 5, wherein the alkylcarboxyl group has 2-18 carbon atoms.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95944240A EP0801563B1 (en) | 1994-12-30 | 1995-12-21 | The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome |
| JP8521126A JPH10511953A (en) | 1994-12-30 | 1995-12-21 | Utilization of 2,3-alkylcarboxybenzoic acid in adult respiratory distress syndrome |
| AT95944240T ATE235238T1 (en) | 1994-12-30 | 1995-12-21 | USE OF 2,3-ALKYLCAEBONYLOXYBENZOIC ACID FOR THE TREATMENT OF RESPIRATORY UNAWARENESS SYDROME IN ADULTS |
| DE69530120T DE69530120T2 (en) | 1994-12-30 | 1995-12-21 | USE OF 2,3-ALKYLCAEBONYLOXYBENZOIC ACID FOR THE TREATMENT OF BREATHING TEMPERATURE IN ADDITIVES |
| AU46090/96A AU4609096A (en) | 1994-12-30 | 1995-12-21 | The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/366,885 US5504111A (en) | 1994-12-30 | 1994-12-30 | Use of 2,3 alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome |
| US08/366,885 | 1994-12-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996020702A1 WO1996020702A1 (en) | 1996-07-11 |
| WO1996020702B1 true WO1996020702B1 (en) | 1996-08-22 |
Family
ID=23444992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/016892 Ceased WO1996020702A1 (en) | 1994-12-30 | 1995-12-21 | The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5504111A (en) |
| EP (2) | EP0801563B1 (en) |
| JP (1) | JPH10511953A (en) |
| AT (2) | ATE337789T1 (en) |
| AU (1) | AU4609096A (en) |
| DE (2) | DE69530120T2 (en) |
| WO (1) | WO1996020702A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955496A (en) * | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
| US6174695B1 (en) | 1997-08-12 | 2001-01-16 | The Regents Of The University Of California | Epoxide hydrolase inhibitor methods |
| WO2004032825A2 (en) * | 2001-11-02 | 2004-04-22 | Advanced Life Sciences, Inc. | Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax |
| WO2004010989A1 (en) * | 2002-07-25 | 2004-02-05 | Advances Life Sciences, Inc. | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3270988D1 (en) * | 1981-07-20 | 1986-06-12 | Upjohn Co | Use of ibuprofen or flurbiprofen for the manufacture of a medicament for treating respiratory disorders |
| US4443476A (en) * | 1981-07-20 | 1984-04-17 | The Upjohn Company | Treatment of adult respiratory distress syndrome |
| US4447451A (en) * | 1981-07-20 | 1984-05-08 | The Upjohn Manufacturing Company M | Treatment of adult respiratory distress syndrome |
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| US4703040A (en) * | 1985-04-03 | 1987-10-27 | Markov Angel K | Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP) |
| US5198420A (en) * | 1989-10-02 | 1993-03-30 | The General Hospital Corporation | Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome |
| IE911697A1 (en) * | 1990-05-24 | 1991-12-04 | Zeneca Ltd | Therapeutic agent |
| JP2925391B2 (en) * | 1992-01-09 | 1999-07-28 | サントリー株式会社 | Pharmaceutical composition for treating ARDS |
| US5389522A (en) * | 1993-03-19 | 1995-02-14 | Repine; John E. | Serum antioxidants as predictors of the adult respiratory distress syndrome in septic patients |
-
1994
- 1994-12-30 US US08/366,885 patent/US5504111A/en not_active Expired - Lifetime
-
1995
- 1995-12-21 DE DE69530120T patent/DE69530120T2/en not_active Expired - Fee Related
- 1995-12-21 WO PCT/US1995/016892 patent/WO1996020702A1/en not_active Ceased
- 1995-12-21 EP EP95944240A patent/EP0801563B1/en not_active Expired - Lifetime
- 1995-12-21 AT AT02009331T patent/ATE337789T1/en not_active IP Right Cessation
- 1995-12-21 JP JP8521126A patent/JPH10511953A/en active Pending
- 1995-12-21 AU AU46090/96A patent/AU4609096A/en not_active Abandoned
- 1995-12-21 DE DE69535210T patent/DE69535210T2/en not_active Expired - Fee Related
- 1995-12-21 EP EP02009331A patent/EP1226821B1/en not_active Expired - Lifetime
- 1995-12-21 AT AT95944240T patent/ATE235238T1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2114014A1 (en) | Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine | |
| CA2213339A1 (en) | Method of treating adenosine depletion | |
| EP1234586A3 (en) | Hepatoselective pharmaceutical actives | |
| CA2276170A1 (en) | Sustained analgesia achieved with buprenorphine | |
| MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
| AU1358695A (en) | Nasal administration | |
| CA2093806A1 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| WO2000004894A3 (en) | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | |
| BR9807319A (en) | Microgranules with controlled release, for oral administration, containing cisplatin, preparation process, pharmaceutical preparation, and use of microgranules. | |
| CA2240717A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| RO116343B1 (en) | Pharmaceutical composition and method for treating bacterial infections in pediatric patients | |
| KR910005858A (en) | Fatty acid therapy | |
| US6140307A (en) | Pharmaceutical composition | |
| TW367326B (en) | Pyrimidine derivative, process for the preparation thereof and a pharmaceutical composition containing same | |
| WO1996020702B1 (en) | The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome | |
| CA2159485A1 (en) | Anti-oxydant alkylaryl polyether alcohol polymers | |
| KR910009259A (en) | Pyrimidone derivatives and homologues for the treatment of asthma or certain skin diseases | |
| CA2216789A1 (en) | Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers | |
| EP0175440A3 (en) | Method of treating migraine headaches | |
| US6900181B2 (en) | Pharmaceutical composition | |
| AU7439996A (en) | Novel uses of mammalian ctla-8 and related reagents | |
| EP1226821A3 (en) | The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome | |
| EP0753309A2 (en) | Preparation of lactoferrin (or analogous proteins) and desferrioxamine methanesulfonate (or other metal ion chelators) for the therapy of viral infectious diseases | |
| JPS5626819A (en) | Preventive for hypoimmunity |